← Eichor
Condition: Metastatic Solid Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Solid Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
Phase 3 · 4 location(s) · Mayo Clinic · NCT03750227Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid T
Phase 1 · 11 location(s) · Qurgen Inc. · NCT06873659Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT02830724Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Phase 1 · 3 location(s) · Adlai Nortye Biopharma Co., Ltd. · NCT07252479A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1 · 16 location(s) · Coherus Oncology, Inc. · NCT05635643Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Phase N/A · 140 location(s) · National Cancer Institute LAO · NCT02474160HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT05681650RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT07030569This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and
Phase 1 · 8 location(s) · ABL Bio, Inc. · NCT04762641Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unrese
Phase 1 · 4 location(s) · National Cancer Institute (NCI) · NCT05111561Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metas
Phase 1 · 5 location(s) · Kiromic BioPharma Inc. · NCT06069570Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 · 7 location(s) · Sairopa B.V. · NCT05856981A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic
Phase 1/Phase 2 · 40 location(s) · Suzhou Transcenta Therapeutics Co., Ltd. · NCT04495296FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced
Phase 1 · 3 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT04443088A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Xuanzhu Biopharmaceutical Co., Ltd. · NCT04996121A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and
Phase 1 · 9 location(s) · Boehringer Ingelheim · NCT07607678First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Se
Phase 1 · 3 location(s) · Molecure S.A. · NCT05759923A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07202364Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Phase 1 · 7 location(s) · Hanmi Pharmaceutical Company Limited · NCT06724016Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1 · 3 location(s) · ImmVirx Pty Ltd · NCT05427487A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07279428Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06549478PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostat
Phase 2/Phase 3 · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07426055Intratumoral CAN2109 in Subjects With Solid Tumors
Phase 1 · 1 location(s) · Canwell Biotech Limited · NCT06332430GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Phase 1 · 5 location(s) · Grit Biotechnology · NCT05430373A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Phase 1 · 2 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT05746897BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.